Nivolumab: tested with established drugs
136 studies: they are given beside it. Page 1 of 2. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- bNAbs and Anti-PD-1 in HIVRecruitingNCT07820813Phase 2Report a problem
- NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain TumorsRecruitingNCT07664176Phase 1Report a problem
- Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHLRecruitingNCT07551583Phase 2Report a problem
- Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung CancerRecruitingNCT07084610Phase 2Report a problem
- Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCRecruitingNCT07050043Phase 3Report a problem
- Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and RelatlimabRecruitingNCT06816927Phase 2Report a problem
- Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell CarcinomaRecruitingNCT06288191Phase 2Report a problem
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingNCT06203600Phase 2/3Report a problem
- Neoadjuvant Nivolumab and Relatlimab in Merkel Cell CarcinomaRecruitingNCT06151236Phase 2Report a problem
- Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric CancerRecruitingNCT05859477Phase 2Report a problem
- Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver TransplantationRecruitingNCT05475613Phase 2Report a problem
- Low Dose Nivolumab in Adults Living With HIV on Antiretroviral TherapyRecruitingNCT05187429Phase 1/2Report a problem
- Radiation Free Chemotherapy for Early Hodgkin LymphomaRecruitingNCT04866654Phase 2Report a problem
- Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in MelanomaRecruitingNCT04741997Early Phase 1Report a problem
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingNCT04566380Phase 2Report a problem
- Induction Chemo-Nivo in Unresectable Stage III NSCLCTerminatedNCT06003075Phase 2Results postedReport a problem
- A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCompletedNCT05297565Phase 3Results postedReport a problem
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadActive, not recruitingNCT04810078Phase 3Results postedReport a problem
- Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular CarcinomaActive, not recruitingNCT04658147Phase 1Results postedReport a problem
- A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsCompletedNCT04567615Phase 2Results postedReport a problem
- Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal CancerTerminatedNCT04458909Phase 3Results postedReport a problem
- Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. NivolumabCompletedNCT04401995Phase 2Results postedReport a problem
- A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TerminatedNCT04149574Phase 3Results postedReport a problem
- Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCompletedNCT04109066Phase 3Results postedReport a problem
- A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerCompletedNCT04100018Phase 3Results postedReport a problem
- A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCompletedNCT04075604Phase 2Results postedReport a problem
- A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerActive, not recruitingNCT04025879Phase 3Results postedReport a problem
- Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.CompletedNCT03980925Phase 2Results postedReport a problem
- Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerCompletedNCT03894891Phase 2Results postedReport a problem
- Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHNCompletedNCT03878979Phase 2Results postedReport a problem
- Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)CompletedNCT03742986Phase 2Results postedReport a problem
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)CompletedNCT03689699Phase 1/2Results postedReport a problem
- A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)CompletedNCT03656718Phase 1/2Results postedReport a problem
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaTerminatedNCT03646123Phase 2Results postedReport a problem
- Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasCompletedNCT03586999Phase 1/2Results postedReport a problem
- COMbination of Bipolar Androgen Therapy and NivolumabCompletedNCT03554317Phase 2Results postedReport a problem
- BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical CancerTerminatedNCT03527264Phase 2Results postedReport a problem
- A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerTerminatedNCT03519308Early Phase 1Results postedReport a problem
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedNCT03519256Phase 2Results postedReport a problem
- Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results postedReport a problem
- An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadCompletedNCT03414983Phase 2/3Results postedReport a problem
- Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerCompletedNCT03414684Phase 2Results postedReport a problem
- Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT03382561Phase 2Results postedReport a problem
- Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell CarcinomaTerminatedNCT03278626Phase 1/2Results postedReport a problem
- Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)CompletedNCT03267498Phase 2Results postedReport a problem
- Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)CompletedNCT03117049Phase 3Results postedReport a problem
- A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadCompletedNCT03098550Phase 1/2Results postedReport a problem
- Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer PatientsCompletedNCT03081689Phase 2Results postedReport a problem
- Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorTerminatedNCT03041181Phase 2Results postedReport a problem
- Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced MelanomaCompletedNCT03033576Phase 2Results postedReport a problem
- Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLCTerminatedNCT02768558Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedNCT02726581Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)CompletedNCT02667587Phase 3Results postedReport a problem
- Nivolumab With DC Vaccines for Recurrent Brain TumorsCompletedNCT02529072Phase 1Results postedReport a problem
- Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLCActive, not recruitingNCT02259621Phase 2Results postedReport a problem
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedNCT02231749Phase 3Results postedReport a problem
- Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)CompletedNCT02181738Phase 2Results postedReport a problem
- A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCompletedNCT02060188Phase 2Results postedReport a problem
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)CompletedNCT02041533Phase 3Results postedReport a problem
- A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCompletedNCT02017717Phase 3Results postedReport a problem
- Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.CompletedNCT01928576Phase 2Results postedReport a problem
- A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT01928394Phase 1/2Results postedReport a problem
- Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCompletedNCT01927419Phase 2Results postedReport a problem
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedNCT01844505Phase 3Results postedReport a problem
- Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)CompletedNCT01783938Phase 2Results postedReport a problem
- PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCompletedNCT01621490Phase 1Results postedReport a problem
- An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCompletedNCT01592370Phase 1/2Results postedReport a problem
- Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaCompletedNCT01585194Phase 2Results postedReport a problem
- Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)CompletedNCT01472081Phase 1Results postedReport a problem
- Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)CompletedNCT01454102Phase 1Results postedReport a problem
- A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06946797Phase 2Report a problem
- Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabActive, not recruitingNCT06237920Phase 2Report a problem
- Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT06188676Phase 3Report a problem
- Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's LymphomaStatus unknownNCT05772624Phase 2Report a problem
- Nivolumab Combined With SOX Used in the Perioperative TreatmentStatus unknownNCT05739045Phase 2Report a problem
- A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWithdrawnNCT05496192Phase 2Report a problem
- Fedratinib in Combination With NivolumabCompletedNCT05393674Phase 2Report a problem
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingNCT05308446Phase 2Report a problem
- Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCCStatus unknownNCT05213312Phase 2/3Report a problem
- Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTIONTerminatedNCT04901988Phase 2/3Report a problem
- A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid MalignanciesCompletedNCT04850755Phase 1Report a problem
- Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric CancerStatus unknownNCT04782791Phase 2Report a problem
- Immune Profile and Prognosis of Malignant Liver Tumors With Radiofrequency Ablation (RFA) TherapyCompletedNCT04707547Phase 4Report a problem
- Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell CarcinomasStatus unknownNCT04570683Early Phase 1Report a problem
- New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyActive, not recruitingNCT04564157Phase 3Report a problem
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder CancerActive, not recruitingNCT04506554Phase 2Report a problem
- EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer PatientsActive, not recruitingNCT04444921Phase 3Report a problem
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerActive, not recruitingNCT04380545Phase 1/2Report a problem
- Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCCSuspendedNCT04268888Phase 2/3Report a problem
- Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell LymphomaWithdrawnNCT04230330Phase 1Report a problem
- Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsCompletedNCT04205552Phase 2Report a problem
- Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBMActive, not recruitingNCT04195139Phase 2Report a problem
- Nivolumab with Chemotherapy in Pleural Mesothelioma After SurgeryCompletedNCT04177953Phase 2Report a problem
- Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung CancerTerminatedNCT04173325Phase 1Report a problem
- A Study of Nivolumab and Chemotherapy Followed by Surgery for MesotheliomaActive, not recruitingNCT04162015Phase 1Report a problem
- Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary MelanomaCompletedNCT04133948Phase 1/2Report a problem
- Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk MyelodysplasiaWithdrawnNCT04128020Phase 1Report a problem
- Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04123379Phase 2Report a problem
- Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to TreatmentActive, not recruitingNCT04106414Phase 2Report a problem
- Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Phase 2/3Report a problem